Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment.
Cognitive impairment is found in up to 70% of patients with multiple sclerosis (MS). Once thought of as a variant of subcortical dementia with a characteristic set of deficits, we now know that MS-related cognitive impairment can have many faces. This conceptual change in neuropsychology is embedded in a paradigm shift in the neuroscientific understanding of MS over the past 25 years: Partly based on modern neuroimaging techniques, the classical view of MS as an inflammatory demyelinating disease affecting the white matter of the central nervous system has been extended. In particular, many studies have shown that the MS pathology also includes neurodegeneration, and that gray matter structures such as the cerebral cortex can also show focal lesions, atrophy, or both. The authors present an updated summary of the clinical manifestation and neuroimaging correlates of cognitive impairment in MS, and discuss the relatively few treatment options available to date.
Center for Neurology and Neurorehabilitation, State Hospital/Luzerner Kantonsspital, Luzern, Switzerland.
Tobias
T
Pflugshaupt
Unit of Neuropsychology, Department of Neurology, University Hospital Zürich, Zürich, Switzerland.
Olivia
O
Geisseler
Center for Neurology and Neurorehabilitation, State Hospital/Luzerner Kantonsspital, Luzern, Switzerland.
Thomas
T
Nyffeler
Unit of Neuropsychology, Department of Neurology, University Hospital Zürich, Zürich, Switzerland.
Michael
M
Linnebank
D003072:Cognition Disorders / Q000209:etiology*; D060825:Cognitive Dysfunction / Q000209:etiology*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009103:Multiple Sclerosis / Q000150:complications*; D059906:Neuroimaging